Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the...

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene...